
==== Front
Turk J Med Sci
Turk J Med Sci
Turkish Journal of Medical Sciences
1300-0144
1303-6165
Scientific and Technological Research Council of Turkey (TUBITAK)

10.55730/1300-0144.5838
tjmed-54-04-688
Research Article
Can volumetric magnetic resonance imaging evaluations be helpful in the follow-up of cognitive functions in cognitively normal Parkinson’s disease patients?
https://orcid.org/0000-0002-4867-304X
UYSAL Hasan Armağan 1*
https://orcid.org/0000-0003-0278-258X
HÜNERLİ Duygu 2
https://orcid.org/0000-0002-0194-7779
ÇAKMUR Raif 3
https://orcid.org/0000-0002-5143-236X
DÖNMEZ ÇOLAKOĞLU Beril 3
https://orcid.org/0000-0002-0463-0945
ADA Emel 4
https://orcid.org/0000-0002-7756-4387
YENER Görsev 56
1 Department of Neurology, İzmir University of Economics, Medical Point Hospital, İzmir, Turkiye
2 Department of Neuroscience, Institute of Health Sciences, Dokuz Eylül University, İzmir, Turkiye
3 Department of Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye
4 Department of Radiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye
5 Faculty of Medicine, İzmir University of Economics, İzmir, Turkiye
6 İzmir Biomedicine and Genome Center, İzmir, Turkiye
* Correspondence: druysalarmagan@yahoo.com
2024
05 1 2024
54 4 688699
30 9 2023
23 8 2024
05 1 2024
© TÜBİTAK
2024
https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License.
Background/aim

In this study, besides the evaluation of gray and white matter changes in cognitively normal Parkinson’s disease (PD-CN) patients with volumetric magnetic resonance imaging (MRI) parameters, it was tried to show that some neuropsychological tests may be impaired in PD-CN patients.

Materials and methods

Twenty-six PD-CN patients and 26 healthy elderly (HC) participants were included in the current study. Global cognitive status was assessed using the mini-mental state examination (MMSE), and the Montreal cognitive assessment scale (MoCA). Attention and executive functions were evaluated using the Wechsler memory scale-revised (WMS-R) digit span test and trail making test (TMT) part A and part B, the Stroop test, semantic and phonemic fluency tests, and clock drawing test. Magnetic resonance imaging (MRI) was acquired according to the Alzheimer’s disease neuroimaging initiative (ADNI) protocol.

Results

There were no significant differences among groups regarding age, sex, handedness, and years of education. In the comparison of the PD-CN group and the HC group, there was a statistical decrease in the total animal scores, lexical fluency, TMT part A and TMT part B scores in the PD-CN group. Subcortical gray matter volumes (GMV) were significantly lower in PD-CN patients. The PD-CN group had a significantly reduced total volume of right putamen and left angular gyrus compared to that in the HC group. We observed that putamen and angular gyrus volumes were lower in PD-CN patients. On the other hand, TMT part B may be a useful pretest in detecting the conversion of mild cognitive impairment in PD.

Conclusion

Significant MRI volumetric measurements and neuropsychological test batteries can be helpful in the clinical follow-up in PD-CN patients.

Parkinson’s disease
volumetric MRI
cognitive function
Wechsler memory scale-revised
trail making test
==== Body
pmc1. Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease and mainly affects the motor system [1]. Besides motor symptoms, nonmotor symptoms such as anosmia, sleep disorders, autonomic findings, pain, depression, anxiety, apathy, and cognitive impairment can occur at any stage of the disease, even before motor symptoms. The causes of cognitive dysfunction in PD are not fully understood, and a rate that is 25% in the early stages of the disease may increase to 80% in the late stages. It has been shown in many studies that there is volume loss in occipital, parietal, and frontal cortices, as well as atrophy in the hippocampus, in PD with cognitive dysfunction [2–3]. There are few studies showing cortical and subcortical tissue volume loss in cognitively normal PD (PD-CN) patients without a diagnosis of cognitive impairment [4–9]. Testing of multiple cognitive areas in neuropsychological evaluation is quite difficult due to the lack of access to trained neuropsychologists and the variation in the educational and cultural levels of the patients [10]. Previous studies have demonstrated that neuropsychological assessments may be impaired in patients with Parkinson’s disease within normal cognitive test scores ranges [11–12].

The aim of this study is to evaluate gray and white matter changes in PD-CN patients with volumetric magnetic resonance imaging (MRI) parameters. In addition, we aimed to highlight that some neuropsychological tests may be impaired in PD-CN patients.

2. Methods

2.1. Participant selection

Twenty-six PD-CN patients (mean age 65.69 ± 9.20 years; six females, and 20 males) and 26 healthy elderly participants (HC) (mean age 66. 38 ± 6.84 years; eight females, and 18 males) were included in the current study. Patients with PD-CN were recruited from the Movement Disorders Outpatient Clinic in the Department of Neurology at Dokuz Eylül University Hospital. The diagnosis of idiopathic PD was clinically determined based on the UK Parkinson’s Disease Society Brain Bank criteria [13]. The severity of motor symptoms was assessed by the unified Parkinson’s disease rating scale (UPDRS) part III [14] whereas disease severity was examined using the Hoehn and Yahr scale [15].

The inclusion criteria for patients with PD-CN were as follows: (1) a clinical diagnosis of idiopathic PD; (2) controlled motor symptoms with stable dopaminergic treatment; and (3) Hoehn and Yahr stage III or less. The exclusion criteria for PD-CN group were as follows: (1) a clinical diagnosis of PD-mild cognitive impairment [16] and PD-dementia [17], supported by detailed neuropsychological assessments; (2) a history of psychiatric disorders and/or visual hallucinations with the use of medications affecting cognition (e.g., antidepressants, antipsychotics); (3) a history of drug-induced dopamine dysregulation; (4) the presence of and/or a history of vascular lesions, head trauma, seizures, and/or strokes; (5) severe tremors preventing MRI scans; and (6) treatment with deep brain stimulation, jejunal levodopa, and/or subcutaneous apomorphine. Accordingly, one patient was excluded due to severe motion artifacts in MRIs.

An additional 26 healthy elderly participants were recruited from various community sources through bulletin board announcements. The exclusion criteria for the healthy elderly group were as follows: (1) a history or presence of any neurological abnormalities and/or cognitive impairment (mini-mental state examination, MMSE, scoring ≤27), (2) a history of psychiatric disorders, cerebral atrophy, vascular lesions, head trauma, seizures, strokes, alcohol and/or drug abuse/misuse. Participants with depressive symptoms (scoring >14 on the Yesavage geriatric depression scale, GDS [18–19]) were also excluded from all groups.

All PD-CN patients were undergoing the following anti-Parkinsonian treatment at the time of assessments: L-dopa monotherapy (n = 9), dopamine agonist monotherapy (n = 4), MAO-B inhibitor (n = 1), or a combined treatment (n = 12). Levodopa equivalent daily doses (LEDD) were calculated using a standardized formula for all the dopamine replacement therapies that the PD-CN patients were receiving [20]. The neuropsychological and volumetric MRI assessments of the PD-CN patients were conducted during their “on” periods.

All subjects in this study were participants in the prior study by Hünerli-Gündüz et al. [21]. All participants were provided with written informed consent prior to their voluntary participation in the study. The study protocol was approved by the Non-Invasive Research Ethics Board of Dokuz Eylul University with the approval number of 2018-10-38 on April 12, 2018.

2.2. Neuropsychological assessment

Neuropsychological performance was evaluated by trained neuropsychologists. Global cognitive status was assessed using the mini-mental state examination (MMSE, [22]) and the Montreal cognitive assessment scale (MoCA, [23]). Attention and executive functions were evaluated using the Wechsler memory scale-revised (WMS-R) digit span test [24], trail making test (TMT) parts A and B [25], the Stroop test [26], semantic and phonemic fluency tests, and clock drawing test [27].

2.3. MRI acquisition, preprocessing, and analysis

MRI scans was acquired according to the Alzheimer’s disease neuroimaging initiative (ADNI)1 protocol. For each subject, a high-resolution T1-weighted volumetric MRI scan was obtained at the Dokuz Eylül University Neuroradiology Unit, İzmir, Türkiye, using a 1.5 Tesla Philips Achieva system. This included coronal 3D T1-weighted TFE sequences (TR: 9 ms, TE: 4 ms, FOV: 240 mm, matrix: 256, slice thickness: 1 mm, and NSA: 1). Gray matter volume measurements were performed with the CAT12 Toolbox (Computational Anatomy Toolbox)2 within the MATLAB-based (Mathworks, Sherborn, MA, USA) SPM12 software3.

First, 3D T1-weighted images were converted from DICOM format to NIFTI format. Secondly, the starting points of the images were manually adjusted so that the x, y, z coordinates of the anterior commissure corresponded to the (0, 0, 0) point. This adjustment aligned the MRI images with the Montreal Neurological Institute (MNI) template. Finally, the segmentation process was performed using the parameters recommended in the CAT12 user manual.

As a result of the segmentation process, the 3D T1-weighted images were separated into gray matter, white matter, and cerebrospinal fluid. The CAT12 “Estimate Mean Values inside Region of Interest (ROI)” function was applied using the LPBA40 (LONI Probabilistic Brain Atlas, 101) atlas to obtain mean volume values for different ROIs. Average volume values for each ROI were then extracted separately.

Gray matter volumes (GMV) were also normalized to account for differences in head size among individuals. The normalization process was performed by multiplying each volume value by the volumetric normalization coefficient automatically calculated by SIENAX (an adaptation of SIENA— Structural Image Evaluation, using Normalization, of Atrophy—for crosssectional measurement) [28].

2.4. Statistical analysis

SPSS 25.0 (IBM Corporation, Armonk, NY, USA) and MedCalc 14 (MedCalc Software Ltd, Ostend, Belgium) programs were used to analyze the variables. The conformity of the data to a normal distribution was assessed using the Shapiro–Francia test, while the homogeneity of variance was evaluated with the Levene’s test. In the comparison of two independent groups based on quantitative variables, the independent samples t-test was used with the Bootstrap results, while the Mann–Whitney U test was used with the Monte Carlo results. For the comparison of the categorical variables, with each other, the Pearson chi-squared and Fisher’s exact tests were assessed using the Monte Carlo simulation technique. Sensitivity, specificity, positive predictive value, and negative predictive value ratios for the relationship between the classification of the cut-off value were calculated according to the variables and the actual classification. These metrics were analyzed and expressed using receiver operating curve (ROC) analysis. The logistic regression analysis was performed using the Backward method to determine the cause-effect relationship between the categorical dependent variable and the explanatory variables. Quantitative variables were expressed as mean (standard deviation) and median (minimum–maximum) in the tables, while categorical variables were shown as n (%). The variables were analyzed at a 95% confidence level, and a p-value of less than 0.05 was considered significant.

3. Results

The demographic, clinical, and neuropsychological characteristics of the patients and healthy controls are presented in Tables 1 and 2. There were no significant differences among the groups regarding age, sex, handedness, and years of education.

3.1. Neuropsychological tests of PD-CN

In the comparison between the PD-CN group and the HC group, there was a statistically significant decrease in the total animal scores, lexical fluency, TMT part A, and TMT part B scores in the PD-CN group (Table 2). The ROC curves for the neuropsychological test scores were demonstrated in Figure 1. Figure 1a represents the total animal score, Figure 1b indicates the K-A-S score, Figure 1c shows the trail making test part A score, and Figure 1d presents the trail making test part B score.

3.2. Volumetry

There was a statistically significant decrease in the volumes of the right putamen and left angular gyrus in the PD-CN patients compared to healthy controls. Figure 2 demonstrates the subcortical GMV volume differences between PD patients and healthy controls. A comparison of white matter density changes between the PD-CN and HC groups revealed no significant differences (Tables 3 and 4). The ROC curves for MRI volumetric analysis correlation graphs were presented in Figure 3; Figure 3a represents left angular gyrus, Figure 3b the left inferior frontal gyrus, Figure 3c the left middle frontal gyrus, Figure 3d the right middle frontal gyrus, Figure 3e the right putamen, and Figure 3f the right superior frontal gyrus.

3.3. Correlation between volumetry and NPT

Regarding the correlations between volumetric analysis and neuropsychological tests in PD-CN, a significant effect was observed between the reduction in putamen and angular gyrus volume and the decline in executive function in PD-CN patients (Table 4).

4. Discussion

Cognitive impairments in PD are not limited to a specific cognitive area. Cognitive function declines gradually and heterogeneously in PD, with numerous regions potentially contributing to this decline. There is no standardized neuropsychological test or radiological parameter for the early detection of cognitive dysfunction that accompanies PD. This situation becomes particularly challenging in PD-CN. In the current study, TMT part B, within an extensive neuropsychological test battery, demonstrated differences at the group level in PD-CN. It is noteworthy that commonly employed screening tools, such as MMSE [29,30] and MoCA [31], may remain unimpaired even at the group level during the phase of normal cognition in PD. Since executive functions are among the first to be disrupted in PD, TMT part B may be impaired. Global cognitive scales such as MMSE and MOCA may not reflect the initial impairment in executive function [32–33]. Therefore, TMT part B may be a useful test for detecting cognitive impairment in PD-CN patients.

The volumetric MRI findings of subcortical gray matter in PD-CN patients in the present study indicated a decrease in the volumes of the right putamen and left angular gyrus compared to healthy controls. This finding implies that regional GMV loss occurs in the earliest stages of the disease, even in cognitively intact patients.

The role of subcortical structures in cognition remains elusive. Several recent studies on healthy participants have demonstrated that a higher putamen volume has positive effects on attention and executive functions [3, 34–37]. Previous studies have frequently reported diffuse cortical atrophy in limbic, temporal, prefrontal, occipital, and parietal areas in PD patients with cognitive impairment and dementia [2, 7, 38]. However, information on PD-CN patients is scarce and diverse. Several studies have indicated normal cortical volume in patients with PD-MCI [39–41], while others report dysfunction in temporal, parietal, and occipital cortical involvement patterns [4–9]. The literature shows that GMV loss becomes more prominent in the temporal, parietal, and frontal regions in PD with mild cognitive impairment [1,7,42], and widespread GMV loss occurs as the disease progresses to the dementia phase [36,43–47].

In the present study, we also found that diminished performance on TMT part B test in PD-CN patients was associated with reductions in the volumes of the putamen and angular gyrus, as well as declines in executive function. In the meta-analysis by He et al. [34], structural and functional changes in the brains of PD patients occur at different rates and in different brain regions. Furthermore, increasing gray matter loss as the disease progresses leads to functional deterioration. Atrophy was prominent in the midcingulate gyrus and right supramarginal gyrus in PD-MCI, and in the left insula spreading to the bilateral insular area in PD with dementia.

The pentagon copying test in PD patients without dementia has been shown to be significantly associated with volumetric reductions in cortical regions such as the right complement motor area, left rostral midfrontal cortex, pars triangularis, and left cuneus. This study demonstrated that subtle changes in multiple cognitive domains in PD without dementia are associated with regional volumes in certain systems that play a role in the development of cognitive impairment [9]. Another study showed that both the MMSE and the pentagon copying test reflected regional brain degeneration often found in posterior regions, but that the pentagon copying test was associated with more areas and larger cluster sizes [48]. In a study using TMT B-A scores (the time difference between performance on TMT part A and TMT part B), significant negative correlations were detected bilaterally in the left precentral/middle frontal cortex, right posterior cingulate area, anterior cingulate, and complementary motor area. In addition, it was specifically stated that low GM volume values in these regions may be associated with high TMT B-A time scores [49]. Our data support the use of TMT part B as a tool in patient care to monitor the development of cognitive status in PD-CN patients.

One of the limitations of the current study is the small number of cases and the fact that it was conducted at a single tertiary institution. Another important point is that identifying patients who progress to PD-MCI and determining which neuropsychological test scores decline over time may be crucial. This study will enable a more thorough exploration to establish how certain neuropsychological tests are associated with cortical and subcortical structural alterations as PD-MCI develops. In this study, the demographic variables and clinical characteristics of PD patients were well matched to eliminate the possible confounding effects of age, sex, education, hand dominance, medication use, and disease onset on our results. We suggest that the subcortical volume reductions detected in volumetric MRI can be used as a tool in the follow-up of cognitive functions in PD-CN patients.

5. Conclusion

As a remarkable result of our study, we observed that putamen and angular gyrus volumes were lower in PD-CN patients at the group level. On the other hand, TMT part B may be a useful pretest in detecting the conversion of mild cognitive impairment in PD. Therefore, significant MRI volumetric measurements and neuropsychological test batteries can be helpful in the clinical follow-up of PD-CN patients.

Figure 1 Total animal score (a), K-A-S (b), trail making test part A (c), and part B (d).

Figure 2 Subcortical GMV volume differences between PD patients and healthy controls.

Figure 3 MRI volumetric analysis correlation graphs. Left angular gyrus (a), left inferior frontal gyrus (b), left middle frontal gyrus (c), right middle frontal gyrus (d), right putamen (e), right superior frontal gyrus (f).

Table 1 The demographic and clinical characteristics of PD patients and healthy controls.

	Total (n = 52)
Mean ± SD	HC-GMV (n = 26)
Mean ± SD	PD-CN GMV (n = 26)
Mean ± SD	p	
Age	66.04 ± 8.03	66.38 ± 6.84	65.69 ± 9.20	0.741	
MMSE	28.79 ± 1.33	29.12 ± 1.11	28.46 ± 1.48	0.077	
	n (%)	n (%)	n (%)		
Sex				0.755	
 Female	14 (26.9)	8 (30.8)	6 (23.1)		
 Male	38 (73.1)	18 (69.2)	20 (76.9)		
Education (years)	11 (5–17)	11 (5–17)	8 (5–15)	0.049 *	
Hand dominance				0.49	
 Left	2 (3.8)	2 (7.7)	0 (0.0)		
 Right	50 (96.2)	24 (92.3)	26 (100.0)		
PD medications					
 Levodopa	9 (34.6)	-	9 (34.6)	-	
 Dopamine agonist	4 (15.4)	-	4 (15.4)	-	
 MAO-B inhibitors	1 (3.8)	-	1 (3.8)	-	
 Combined	12 (46.2)	-	12 (46.2)	-	
	Median (min–max)	-	Median (min–max)		
Hoehn and Yahr score	2 (1–3)	-	2 (1–3)		
UPDRS motor score	22.5 (6–36)	-	22.5 (6–36)		
MOCA score	24.5 (13–30)	-	24.5 (13–30)		
Disease onset (years)	3 (1–10)	-	3 (1–10)	-	
Daily levodopa dose	550 (120–1382)	-	550 (120–1382)	-	
HC, healthy elderly participants (control); PD, Parkinson’s disease; GMV, gray matter volume; SD, standard deviation; MMSE, mini-mental state examination; MoCA, Montreal cognitive assessment; min, minimum; max, maximum; n, number, %, percent;

* p < 0.05.

Table 2 The neuropsychological test scores of PD patients and healthy controls.

	Total (n = 52)
Mean ± SD	HC-GMV (n = 26)
Mean ± SD	PD-CN GMV (n = 26)
Mean ± SD	p	
Volumes					
 GM	41.75 ± 2.47	42.24 ± 2.26	41.27 ± 2.61	0.144	
 WM	36.22 ± 2.27	35.96 ± 2.36	36.49 ± 2.18	0.400	
Matter					
 Gray	41.75 ± 2.47	42.24 ± 2.26	41.27 ± 2.61	0.144	
 White	36.22 ± 2.27	35.96 ± 2.36	36.49 ± 2.18	0.400	
Neuropsychological test scores	
Interference (in seconds)	43.31 ± 13.75	40.81 ± 12.49	45.81 ± 14.72	0.210	
Total animal	22.33 ± 4.44	23.92 ± 4.65	20.73 ± 3.64	0.013	
Total K-A-S	36.06 ± 12.33	40.23 ± 11.87	31.88 ± 11.54	0.014	
	Median (min–max)	Median (min–max)	Median (min–max)		
Total GDS	5 (0–11)	3.5 (0–11)	6 (2–11)	0.065	
Digit span forward	6 (4–8)	5.5 (4–8)	6 (4–8)	0.882	
Digit span backward	4 (3–7)	4 (3–7)	4 (3–6)	0.420	
Total clock drawing	10 (6–10)	10 (8–10)	10 (6–10)	0.112	
Trail making test (measured in the seconds to complete the task)	
Part A	60.31 ± 23.71	50.42 ±14.31	70.19 ± 27.18	0.010*	
Part B	138.27 ± 58.58	112.23 ± 31.91	164.31 ± 67.61	0.004*	
Part B-A	78.62 ± 39.81	61.85 ± 25.01	95.38 ± 44.97	0.004*	
HC, healthy elderly participants (control); PD, Parkinson’s disease; GMV, gray matter volume; SD, standard deviation; min, minimum; max, maximum; n, number, %, percent; GDS, geriatric depression scale;

* p < 0.05;

** p < 0.001

Table 3 The subcortical GMV volumes assessment of the patients and healthy controls.

	Total (n = 52)
Mean ± SD	HC GMV (n = 26)
Mean ± SD	PD-CN GMV (n = 26)
Mean ± SD	p	
Total brain	77.98 ± 3.35	78.20 ± 3.03	77.75 ± 3.69	0.635	
Both side cerebellar lobe	5.84 ± 0.60	5.81 ± 0.64	5.86 ± 0.57	0.803	
Both side brainstem	0.13 ± 0.02	0.13 ± 0.02	0.13 ± 0.02	0.939	
Superior frontal gyrus	
Left	1.91 ± 0.13	1.93 ± 0.10	1.89 ± 0.14	0.286	
Right	1.88 ± 0.13	1.89 ± 0.11	1.86 ± 0.15	0.432	
Middle frontal gyrus	
Left	1.41 ± 0.11	1.43 ± 0.11	1.40 ± 0.10	0.325	
Right	1.45 ± 0.12	1.48 ± 0.13	1.42 ± 0.10	0.046	
Inferior frontal gyrus	
Left	0.66 ± 0.06	0.68 ± 0.07	0.65 ± 0.06	0.036	
Right	0.71 ± 0.06	0.73 ± 0.06	0.70 ± 0.06	0.149	
Precentral gyrus	
Left	0.74 ± 0.08	0.75 ± 0.08	0.73 ± 0.08	0.49	
Right	0.72 ± 0.07	0.72 ± 0.07	0.73 ± 0.06	0.79	
Middle orbitofrontal gyrus	
Left	0.34 ± 0.03	0.35 ± 0.03	0.34 ± 0.04	0.166	
Right	0.35 ± 0.03	0.36 ± 0.03	0.35 ± 0.03	0.116	
Lateral orbitofrontal gyrus	
Left	0.23 ± 0.02	0.23 ± 0.03	0.23 ± 0.02	0.350	
Right	0.20 ± 0.02	0.20 ± 0.02	0.20 ± 0.02	0.753	
Gyrus rectus	
Left	0.13 ± 0.01	0.13 ± 0.01	0.13 ± 0.01	0.831	
Right	0.13 ± 0.01	0.13 ± 0.01	0.13 ± 0.01	0.623	
Postcentral gyrus	
Left	0.61 ± 0.07	0.61 ± 0.07	0.60 ± 0.06	0.682	
Right	0.58 ± 0.06	0.58 ± 0.06	0.58 ± 0.06	0.712	
Superior parietal gyrus	
Left	0.76 ± 0.07	0.76 ± 0.06	0.76 ± 0.07	0.790	
Right	0.75 ± 0.07	0.77 ± 0.07	0.74 ± 0.07	0.216	
Supramarginal gyrus	
Left	0.48 ± 0.04	0.49 ± 0.04	0.48 ± 0.05	0.314	
Right	0.48 ± 0.04	0.48 ± 0.04	0.47 ± 0.05	0.478	
Angular gyrus	
Left	0.62 ± 0.06	0.64 ± 0.05	0.60 ± 0.07	0.022	
Right	0.69 ± 0.07	0.70 ± 0.06	0.68 ± 0.07	0.152	
Precuneus	
Left	0.44 ± 0.05	0.45 ± 0.05	0.44 ± 0.04	0.377	
Right	0.44 ± 0.05	0.45 ± 0.05	0.44 ± 0.05	0.434	
Superior occipital gyrus	
Left	0.24 ± 0.03	0.24 ± 0.03	0.24 ± 0.03	0.815	
Right	0.26 ± 0.03	0.26 ± 0.03	0.25 ± 0.03	0.040	
Middle occipital gyrus	
Left	0.75 ± 0.08	0.77 ± 0.07	0.72 ± 0.08	0.031*	
Right	0.78 ± 0.07	0.78 ± 0.07	0.77 ± 0.07	0.458	
Inferior occipital gyrus	
Left	0.41 ± 0.04	0.42 ± 0.04	0.40 ± 0.05	0.074	
Right	0.42 ± 0.04	0.42 ± 0.04	0.42 ± 0.04	0.603	
Superior temporal gyrus	
Left	1.07 ± 0.07	1.09 ± 0.08	1.06 ± 0.07	0.119	
Right	1.01 ± 0.09	1.03 ± 0.09	1.00 ± 0.08	0.197	
Middle temporal gyrus	
Left	0.91 ± 0.08	0.93 ± 0.08	0.89 ± 0.07	0.138	
Right	0.96 ± 0.08	0.97 ± 0.10	0.95 ± 0.07	0.336	
Inferior temporal gyrus					
Left	0.86 ± 0.06	0.87 ± 0.06	0.85 ± 0.05	0.206	
Right	0.91 ± 0.08	0.92 ± 0.08	0.89 ± 0.07	0.162	
Lingual gyrus	
Left	0.48 ± 0.05	0.48 ± 0.04	0.47 ± 0.05	0.387	
Right	0.49 ± 0.05	0.49 ± 0.04	0.48 ± 0.05	0.176	
Fusiform gyrus	
Left	0.54 ± 0.04	0.55 ± 0.05	0.54 ± 0.04	0.647	
Right	0.53 ± 0.04	0.54 ± 0.04	0.53 ± 0.04	0.489	
Insula	
Left	0.38 ± 0.04	0.38 ± 0.03	0.37 ± 0.04	0.532	
Right	0.36 ± 0.03	0.36 ± 0.03	0.35 ± 0.03	0.581	
Cingulate gyrus	
Left	0.51 ± 0.04	0.52 ± 0.04	0.50 ± 0.04	0.13	
Right	0.58 ± 0.05	0.59 ± 0.04	0.58 ± 0.06	0.321	
Caudate	
Left	0.16 ± 0.02	0.16 ± 0.02	0.16 ± 0.02	0.651	
Right	0.15 ± 0.02	0.15 ± 0.02	0.15 ± 0.02	0.898	
Putamen	
Left	0.23 ± 0.03	0.24 ± 0.03	0.22 ± 0.03	0.056	
Right	0.23 ± 0.03	0.24 ± 0.03	0.22 ± 0.03	0.033*	
Hippocampus	
Left	0.23 ± 0.02	0.23 ± 0.02	0.23 ± 0.02	0.206	
Right	0.24 ± 0.02	0.24 ± 0.02	0.24 ± 0.02	0.252	
Cuneus	
Left	0.21 ± 0.03	0.22 ± 0.02	0.21 ± 0.03	0.315	
Right, median (min–max)	0.23 (0.16–0.26)	0.23 (0.18–0.25)	0.22 (0.16–0.26)	0.107	
Parahippocampal gyrus	
Left, median (min–max)	0.25 (0.18–0.29)	0.24 (0.21–0.29)	0.25 (0.18–0.28)	0.999	
Right	0.25 ± 0.02	0.26 ± 0.02	0.25 ± 0.02	0.317	

Table 4 Subcortical GMV and TMT part B assessment.

Dependent reference	Age and sex adjusted	Age and sex not adjusted	
Group: (PD-CN-GMV)	Odds ratio	95% C.I. for odds ratio	p	Odds ratio	95% C.I. for odds ratio	p	
	
	Lower	Upper	Lower	Upper	
Trail making test part B (>154)	94.1	4.7	1882.1	0.003*	75.6	5.7	997.1	0.001**	
Left Angular Gyrus (≤0.61)	12.7	1.5	111.5	0.022*	9.5	1.5	61.4	0.018*	
Right putamen (≤0.22)	17.2	1.9	152.7	0.011*	11.0	1.7	69.5	0.011*	
	Cut point	PD-CN
GMV	HC
GMV	All	Cut point	PD-CN
GMV	HC
GMV	All	
Predicted ratio	0.617	76.9	92.3	84.6	0.617	80.8	92.3	86.5	

1 Alzheimer’s Disease Neuroimaging Initiative (2016). MRI Acquisition [online]. Website https://www.adni.loni.usc.edu [accessed 30 December 2022].

2 Computational Anatomy Toolbox for SPM (2020). Voxel-based morphometry [online]. Website http://dbm.neuro.uni-jena.de/cat/ [accessed 13 March 2023].

3 Statistical Parametric Mapping (2020). SPM12 software [online]. Website http://www.fil.ion.ucl.ac.uk/spm/software/spm12 [accessed 13 March 2023].

Conflict of interest: The authors declare that they have no conflict of interest.

Informed consent: All participants were provided with written informed consent prior to their voluntary participation in the study. The study protocol was approved by the Non-Invasive Research Ethics Board of Dokuz Eylul University with the approval number of 2018-10-38 on April 12, 2018.

Funding: No funding was taken during the whole process of study, writing the article or preparing the manuscript.
==== Refs
References

1 Gao Y Nie K Huang B Mei M Guo M Changes of brain structure in Parkinson’s disease patients with mild cognitive impairment analyzed via VBM technology Neuroscience Letters 2017 658 29 121 132 10.1016/j.neulet.2017.08.028 28823894
2 Chen B Wang S Sun W Shang X Liu H Functional and structural changes in gray matter of parkinson’s disease patients with mild cognitive impairment European Journal of Radiology 2017 93 16 23 10.1016/j.ejrad.2017.05.018 28668411
3 Hünerli D Emek-Savaş DD Çavuşoğlu B Çolakoğlu BD Ada E Mild cognitive impairment in Parkinson’s disease is associated with decreased P300 amplitude and reduced putamen volume Clinical Neurophysiology 2019 130 8 1208 1217 10.1016/j.clinph.2019.04.314 31163365
4 Ibarretxe-Bilbao N Junque C Tolosa E Marti MJ Valldeoriola F Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson’s disease European Journal of Neuroscience 2009 30 6 1162 1171 10.1111/j.1460-9568.2009.06892.x 19735293
5 Nishio Y Hirayama K Takeda A Hosokai Y Ishioka T Corticolimbic gray matter loss in Parkinson’s disease without dementia European Journal of Neurology 2010 17 8 1090 1097 10.1111/j.1468-1331.2010.02980.x 20298422
6 Song SK Lee JE Park HJ Sohn YH Lee JD The pattern of cortical atrophy in patients with Parkinson’s disease according to cognitive status Movement Disorders 2011 26 2 289 296 10.1002/mds.23477 21370255
7 Ellfolk U Joutsa J Rinne JO Parkkola R Jokinen P Brain volumetric correlates of memory in early Parkinson’s disease Journal of Parkinson’s Disease 2013 3 4 593 601 10.3233/JPD-130276
8 Pagonabarraga J Corcuera-Solano I Vives-Gilabert Y Llebaria G Garcia-Sanchez C Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson’s disease PLoS ONE 2013 8 1 10.1371/journal.pone.0054980
9 Filoteo JV Reed JD Litvan I Harrington DL Volumetric correlates of cognitive functioning in nondemented patients with Parkinson’s disease Movement Disorders 2014 29 3 360 367 10.1002/mds.25633 24038502
10 Filippi M Canu E Donzuso G Stojkovic T Basaia S Tracking cortical changes throughout cognitive decline in Parkinson’s disease Movement Disorders 2020 35 11 1987 1998 10.1002/mds.28228 32886420
11 Yu CC Lu CY Chen MH Chen YS Lu CH Brain atrophy mediates the relationship between misfolded proteins deposition and cognitive impairment in Parkinson’s disease Journal of Personalized Medicine 2021 11 8 702 10.3390/jpm11080702 34442345
12 Dunet V Fartaria MJ Deverdun J Le Bars E Maury F Episodic memory decline in Parkinson’ s disease: relation with white matter hyperintense lesions and influence of quantification method Brain Imaging and Behavior 2019 13 810 818 10.1007/s11682-018-9909-x 29948903
13 Hughes AJ Daniel SE Kilford L Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases Journal of Neurology, Neurosurgery & Psychiatry 1992 55 181 184 10.1136/jnnp.55.3.181 1564476
14 Fahn S Elton RL Unified Parkinson’s disease rating scale Fahn S Marsden CD Calne DB Goldstein M Recent Developments in Parkinson’s Disease 2 Florham Park, NJ, USA Macmillan Healthcare Information 1987 153 163
15 Hoehn MM Yahr MD Parkinsonism: onset, progression and mortality Neurology 1967 17 5 427 442 6067254
16 Litvan I Goldman JG Tröster AI Schmand BA Weintraub D Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines Movement Disorders 2012 27 3 349 356 10.1002/mds.24893 22275317
17 Emre M Aarsland D Brown R Burn DJ Duyckaerts C Clinical diagnostic criteria for dementia associated with Parkinson’s disease Movement Disorders 2007 22 12 1689 1707 10.1002/mds.21507 17542011
18 Yesavage JA Brink TL Rose TL Lum O Huang V Development and validation of a geriatric depression screening scale: a preliminary report Journal of Psychiatric Research 1982 17 1 37 49 10.1016/0022-3956(82)90033-4 7183759
19 Gürvit H Baran B Scales in dementia and cognitive disorders Archives of Neuropsychiatry 2007 44 2 58 65
20 Tomlinson CL Stowe R Patel S Rick C Gray R Systematic review of levodopa dose equivalency reporting in Parkinson’s disease: systematic review of LED reporting in PD Movement Disorders 2010 25 15 2649 2653 10.1002/mds.23429 21069833
21 Hünerli-Gündüz D İşbitiren YÖ Uzunlar H Çavuşoğlu B Çolakoğlu BD Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in Parkinson’s disease with mild cognitive impairment: an event-related oscillation study Neurobiology of Aging 2023 121 88 106 10.1016/j.neurobiolaging.2022.10.001 36395544
22 Folstein MF Folstein SE McHugh PR “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician” Journal of Psychiatric Research 1975 12 3 189 198 10.1016/0022-3956(75)90026-6 1202204
23 Nasreddine ZS Phillips NA Bédirian V Charbonneau S Whitehead V The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment Journal of the American Geriatrics Society 2005 53 4 695 699 10.1111/j.1532-5415.2005.53221.x 15817019
24 Wechsler D WMS-R: Wechsler memory scale-revised San Antonio, TX, USA The Psychological Corporation 1987
25 Reitan RM Wolfson D The Halstead–Reitan neuropsychological test battery and aging Brink TL Clinical Gerontology 1st ed England, UK Routledge 1986 39 61
26 Stroop JR Studies of interference in serial verbal reactions Journal of Experimental Psychology 1935 18 6 643 10.1037/h0054651
27 Manos PJ Wu R The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients The International Journal of Psychiatry in Medicine 1994 24 3 229 244 10.2190/5A0F-936P-VG8N-0F5R 7890481
28 Smith SM Zhang Y Jenkinson M Chen J Matthews PM Accurate, robust, and automated longitudinal and cross-sectional brain change analysis NeuroImage 2002 17 1 479 489 10.1006/nimg.2002.1040 12482100
29 Burdick DJ Cholerton B Watson GS Siderowf A Trojanowski JQ People with Parkinson’s disease and normal MMSE score have a broad range of cognitive performance Movement Disorders 2014 29 1258 1264 10.1002/mds.25924 25073717
30 Roheger M Kalbe E Liepelt-Scarfone I Progression of cognitive decline in Parkinson’s disease Journal of Parkinson’s Disease 2018 8 183 193 10.3233/JPD-181306
31 Dalrymple-Alford J MacAskill MR Nakas CT Livingston L Graham C The MoCA: well-suited screen for cognitive impairment in Parkinson disease Neurology 2010 75 1717 1725 10.1212/WNL.0b013e3181fc29c9 21060094
32 Mamikonyan E Moberg PJ Siderowf A Duda JE Ten Have T Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination (MMSE) scores Parkinsonism & Related Disorders 2009 15 226 231 10.1016/j.parkreldis.2008.05.006 18595765
33 Chou KL Lenhart A Koeppe RA Bohnen NI Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates Parkinsonism & Related Disorders 2014 20 1076 1080 10.1016/j.parkreldis.2014.07.008 25085750
34 He H Liang L Tang T Luo J Wang Y Cui H Progressive brain changes in Parkinson’s disease: a meta-analysis of structural magnetic resonance imaging studies Brain Research 2020 1740 146847 10.1016/j.brainres.2020.146847 32330518
35 van Beilen M Leenders KL Putamen FDOPA uptake and its relationship to cognitive functioning in PD Journal of the Neurological Sciences 2006 248 68 71 10.1016/j.jns.2006.05.033 16782131
36 Sefcsik T Nemeth D Janacsek K Hoffmann I Scialabba J The role of the putamen in cognitive functions—a case study Learning and Perception 2009 1 215 227 10.1556/LP.1.2009.2.4
37 Mak E Zhou J Tan LC Au WL Sitoh YY Cognitive deficits in mild Parkinson’s disease are associated with distinct areas of grey matter atrophy Journal of Neurology, Neurosurgery and Psychiatry 2014 85 576 580 10.1136/jnnp-2013-305805 24133286
38 Wolters AF van de Weijer SCF Leentjens AFG Duits AA Jacobs HIL Resting-state fMRI in Parkinson’s disease patients with cognitive impairment: A meta-analysis Parkinsonism & Related Disorders 2019 62 16 27 10.1016/j.parkreldis.2018.12.016 30580907
39 Weintraub D Doshi J Koka D Davatzikos C Siderowf AD Neurodegeneration across stages of cognitive decline in Parkinson disease Archives of Neurology 2011 68 1562 1568 10.1001/archneurol.2011.725 22159053
40 Melzer TR Watts R MacAskill MR Pitcher TL Livingston L Grey matter atrophy in cognitively impaired Parkinson’s disease Journal of Neurology, Neurosurgery and Psychiatry 2012 83 188 194 10.1136/jnnp-2011-300828 21890574
41 Duncan GW Firbank MJ Yarnall AJ Khoo TK Brooks DJ Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson’s disease? Movement Disorders 2016 31 103 110 10.1002/mds.26312 26202802
42 Dalaker TO Zivadinov R Larsen JP Beyer MK Cox JL Gray matter correlations of cognition in incident Parkinson’s disease Movement Disorders 2010 25 629 633 10.1002/mds.22867 20213820
43 Burton EJ McKeith IG Burn DJ Williams ED O’Brien JT Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls Brain 2004 127 791 800 10.1093/brain/awh088 14749292
44 Pereira JB Ibarretxe-Bilbao N Marti M-J Compta Y Junque C Assessment of cortical degeneration in patients with Parkinson’s disease by voxel-based morphometry, cortical folding, and cortical thickness Human Brain Mapping 2012 33 2521 2534 10.1002/hbm.21378 21898679
45 Agosta F Canu E Stojkovic T Pievani M Tomic A The topography of brain damage at different stages of Parkinson’s disease Human Brain Mapping 2013 34 2798 2807 10.1002/hbm.22101 22528144
46 Lee SH Kim SS Tae WS Lee SY Lee KU Brain volumetry in Parkinson’s disease with and without dementia: where are the differences? Acta Radiologica 2013 54 581 586 10.1177/0284185113476029 23474765
47 Lee JE Cho KH Song SK Kim HJ Lee HS Exploratory analysis of neurchological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson’s disease Journal of Neurology, Neurosurgery and Psychiatry 2014 85 7 16 10.1136/jnnp-2013-305062 23828835
48 Garcia-Diaz AI Segura BB Baggio HC Marti MJ Valldeoriola F Structural MRI correlates of the MMSE and pentagon copying test in Parkinson’s disease Parkinsonism & Related Disorders 2014 20 1405 1410 10.1016/j.parkreldis.2014.10.014 25457818
49 Biundo R Formento-Dojot P Facchini S Vallelunga A Ghezzo L Brain volume changes in Parkinson’s disease and their relationship with cognitive and behavioural abnormalities Journal of the Neurological Sciences 2011 310 64 69 10.1016/j.jns.2011.08.001 21862438
